Scarica l'app Stockscreener
24.68
0.56%
-0.14
Dopo l'orario di chiusura:
25.20
0.52
+2.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Precedente Chiudi:
$24.82
Aprire:
$24.88
Volume 24 ore:
2.72M
Relative Volume:
1.63
Capitalizzazione di mercato:
$4.30B
Reddito:
-
Utile/perdita netta:
$-382.71M
Rapporto P/E:
-9.4198
EPS:
-2.62
Flusso di cassa netto:
$-325.64M
1 W Prestazione:
+30.31%
1M Prestazione:
+53.10%
6M Prestazione:
+52.82%
1 anno Prestazione:
-15.65%
Intervallo 1D:
$24.49
$25.33
Intervallo di 1 settimana:
$19.21
$26.17
Portata 52W:
$12.72
$32.10
Immunovant Inc Stock (IMVT) Company Profile
Nome
Immunovant Inc
Settore
Industria
Telefono
917-580-3099
Indirizzo
320 WEST 37TH STREET, NEW YORK, NY
Confronta IMVT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
24.68 | 4.33B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-14 | Iniziato | Truist | Hold |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-03-03 | Iniziato | Jefferies | Hold |
| 2025-01-03 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-09 | Reiterato | Oppenheimer | Outperform |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2024-03-13 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | JP Morgan | Overweight |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-13 | Aggiornamento | UBS | Neutral → Buy |
| 2023-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Iniziato | BofA Securities | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-31 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2023-02-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Downgrade | UBS | Buy → Neutral |
| 2021-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2021-08-03 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-01 | Downgrade | Stifel | Buy → Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-12 | Iniziato | Guggenheim | Buy |
| 2020-10-08 | Iniziato | Stifel | Buy |
| 2020-10-02 | Iniziato | Credit Suisse | Outperform |
| 2020-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Immunovant Inc Borsa (IMVT) Ultime notizie
Why Immunovant Inc. stock is popular among millennialsJuly 2025 Snapshot & Smart Allocation Stock Tips - newser.com
How analysts rate Immunovant Inc. stock today2025 Buyback Activity & Weekly Return Optimization Alerts - newser.com
Can swing trading help recover from Immunovant Inc. lossesPortfolio Gains Report & Fast Entry Momentum Trade Alerts - newser.com
Analyzing net buyer seller activity in Immunovant Inc.July 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
Key resistance and support levels for Immunovant Inc.2025 EndofYear Setup & Stock Portfolio Risk Control - newser.com
Sentiment analysis tools applied to Immunovant Inc.July 2025 EndofMonth & Weekly Top Gainers Alerts - newser.com
Is Immunovant Inc. stock oversold or undervaluedWeekly Market Report & Precise Entry and Exit Recommendations - newser.com
Will Immunovant Inc. stock go up soonQuarterly Profit Review & Risk Adjusted Buy and Sell Alerts - newser.com
Immunovant (NASDAQ:IMVT) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Immunovant: Takeover Buzz, IMVT-1402 Promise, And Why I'm Staying Neutral (NASDAQ:IMVT) - Seeking Alpha
Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results - Insider Monkey
Will Immunovant Inc. stock outperform value stocksBull Run & Growth-Oriented Investment Plans - newser.com
How institutional ownership impacts Immunovant Inc. stockWeekly Profit Report & Safe Capital Growth Stock Tips - newser.com
Why analysts upgrade Immunovant Inc. stockJuly 2025 Market Mood & Precise Swing Trade Entry Alerts - newser.com
Immunovant gains amid takeover speculation (IMVT:NASDAQ) - Seeking Alpha
How to use Fibonacci retracement on Immunovant Inc.Portfolio Return Summary & Daily Profit Focused Screening - newser.com
IMMUNOVANT Earnings Preview: Recent $IMVT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Immunovant (NASDAQ:IMVT) Shares Up 7.8%What's Next? - MarketBeat
What sentiment indicators say about Immunovant Inc. stockBull Run & Breakout Confirmation Alerts - fcp.pa.gov.br
Graves ophthalmopathy treatment market is expected to reach US$ - openPR.com
What analysts say about Immunovant Inc stockDebt-to-Equity Ratio Analysis & Fast Growing Portfolio Trading - earlytimes.in
Can Immunovant Inc. stock continue upward trendJuly 2025 Summary & Growth Focused Entry Point Reports - Fundação Cultural do Pará
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 - The Manila Times
Immunovant to Report Q2 Financial Results and Provide Business Update on November 10, 2025 - Quiver Quantitative
Immunovant Inc Azioni (IMVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):